Maintenance treatment of depression in old age: A randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy

Archives of General Psychiatry

Volumn 68, Issue 1, 2011, Pages 51-60

  Reynolds III, Charles F ^a   Butters, Meryl A ^a   Lopez, Oscar ^a   Pollock, Bruce G ^a,c   Dew, Mary Amanda ^a   Mulsant, Benoit H ^a,c   Lenze, Eric J ^a,d   Holm, Margo ^a   Rogers, Joan C ^a   Mazumdar, Sati ^b   Houck, Patricia R ^a   Begley, Amy ^a   Anderson, Stewart ^b   Karp, Jordan F ^a   Miller, Mark D ^a   Whyte, Ellen M ^a   Stack, Jacqueline ^a   Gildengers, Ariel ^a   Szanto, Katalin ^a   Bensasi, Salem ^a   Kaufer, Daniel I ^a,e   Kamboh, M Ilyas ^b   DeKosky, Steven T ^a,f   more..

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d WASHINGTON UNIVERSITY   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4; ARIPIPRAZOLE; DONEPEZIL; DULOXETINE; ESCITALOPRAM; PLACEBO;

ABNORMAL DREAMING; AGED; ARTICLE; COGNITION; DAILY LIFE ACTIVITY; DEMENTIA; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MANIA; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TEST; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SLEEP DISORDER;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; AGING; ANTIDEPRESSIVE AGENTS; CHOLINESTERASE INHIBITORS; COGNITION; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDANS; MALE; NOOTROPIC AGENTS; PIPERIDINES; RECURRENCE; TREATMENT OUTCOME;

EID: 78650901362     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archgenpsychiatry.2010.184     Document Type: Article

References (44)

1. Nebes RD, Pollock BG, Houck PR, Butters MA, Mulsant BH, Zmuda MD, Reynolds CF III. Persistence of cognitive impairment in geriatric patients following antidepressant treatment: a randomized, double-blind clinical trial with nortriptyline and paroxetine. J Psychiatr Res. 2003;37(2):99-108.
2. Butters MA, Becker JT, Nebes RD, Zmuda MD, Mulsant BH, Pollock BG, Reynolds CF III. Changes in cognitive functioning following treatment of late-life depression. Am J Psychiatry. 2000;157(12):1949-1954.
3. Bhalla RK, Butters MA, Mulsant BH, Begley AE, Zmuda MD, Schoderbek B, Pollock BG, Reynolds CF III, Becker JT. Persistence of neuropsychologic deficits in the remitted state of late-life depression. Am J Geriatr Psychiatry. 2006;14 (5):419-427.
4. Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry. 2006;63(5):530-538.
5. Steffens DC, McQuoid DR, Potter GG. Outcomes of older cognitively impaired individuals with current and past depression in the NCODE study. J Geriatr Psychiatry Neurol. 2009;22(1):52-61.
6. Salloway S, Ferris S, Kluger A, Goldman R, Griesing T, Kumar D, Richardson S; Donepezil 401 Study Group. Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. Neurology. 2004;63(4):651-657. (Pubitemid 39100820)
7. Lu PH, Edland SD, Teng E, Tingus K, Petersen RC, Cummings JL; Alzheimer's Disease Cooperative Study Group. Donepezil delays progression to AD in MCI subjects with depressive symptoms. Neurology. 2009;72(24):2115-2121.
8. Nobili F, Vitali P, Canfora M, Girtler N, De Leo C, Mariani G, Pupi A, Rodriguez G. Effects of long-term donepezil therapy on rCBF of Alzheimer's patients. Clin Neurophysiol. 2002;113(8):1241-1248. (Pubitemid 34874515)
9. Alexopoulos GS, Meyers BS, Young RC, Campbell S, Silbersweig D, Charlson M. "Vascular depression" hypothesis. Arch Gen Psychiatry. 1997;54(10):915-922.
10. Giacobini E. Is anti-cholinesterase therapy of Alzheimer's disease delaying progression? Aging (Milano). 2001;13(3):247-254.
11. Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, Whalen E. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc. 2001;49(12):1590-1599.
12. Cummings JL. Use of cholinesterase inhibitors in clinical practice: evidencebased recommendations. Am J Geriatr Psychiatry. 2003;11(2):131-145.
13. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006;(1):CD005593.
14. Holmes C, Wilkinson D, Dean C, Vethanayagam S, Olivieri S, Langley A, Pandita-Gunawardena ND, Hogg F, Clare C, Damms J. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology. 2004; 63(2):214-219.
15. Cummings JL, Kaufer D. Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited. Neurology. 1996;47(4):876-883.
16. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C; Galantamine USA-10 Study Group. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology. 2000;54(12):2269-2276.
17. Howard RJ, Juszczak E, Ballard CG, Bentham P, Brown RG, Bullock R, Burns AS, Holmes C, Jacoby R, Johnson T, Knapp M, Lindesay J, O'Brien JT, Wilcock G, Katona C, Jones RW, DeCesare J, Rodger M; CALM-AD Trial Group. Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med. 2007;357(14):1382-1392.
18. Alexopoulos GS, Meyers BS, Young RC, Kalayam B, Kakuma T, Gabrielle M, Sirey JA, Hull J. Executive dysfunction and long-term outcomes of geriatric depression. Arch Gen Psychiatry. 2000;57(3):285-290.
19. Janowsky DS, el-Yousef MK, Davis JM, Sekerke HJ. A cholinergic-adrenergic hypothesis of mania and depression. Lancet. 1972;2(7778):632-635.
20. Sunderland T, Tariot PN, Newhouse PA. Differential responsivity of mood, behavior, and cognition to cholinergic agents in elderly neuropsychiatric populations. Brain Res. 1988;472(4):371-389.
21. Drevets WC, Furey ML. Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial. Biol Psychiatry. 2010;67(5):432-438.
22. First M, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition (SCID-I/P), Version 2.0. New York: New York State Psychiatric Institute; 1995.
23. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960; 23:56-62.
24. Green RC, Cupples LA, Kurz A, Auerbach S, Go R, Sadovnick D, Duara R, Kukull WA, Chui H, Edeki T, Griffith PA, Friedland RP, Bachman D, Farrer L. Depression as a risk factor for Alzheimer disease: the MIRAGE Study. Arch Neurol. 2003; 60(5):753-759.
25. Bhalla RK, Butters MA, Becker JT, Houck PR, Snitz BE, Lopez OL, Aizenstein HJ, Raina KD, DeKosky ST, Reynolds CF III. Patterns of mild cognitive impairment after treatment of depression in the elderly. Am J Geriatr Psychiatry. 2009; 17(4):308-316.
26. Holm MB, Rogers JC. The performance assessment of self-care skills (PASS). In: Hemphill-Pearson B, ed. Assessments in Occupational Therapy Mental Health. 2nd ed. Thorofare, NJ: SLACK; 2008:101-110.
27. National Alzheimer's Coordinating Center. NACC Uniform Data Set (UDS) Coding Guide. Seattle: University of Washington; 2006.
28. Kamboh MI, Aston CE, Hamman RF. The relationship of APOE polymorphism and cholesterol levels in normoglycemic and diabetic subjects in a biethnic population from the San Luis Valley, Colorado. Atherosclerosis. 1995;112(2):145-159.
29. Butters MA, Whyte EM, Nebes RD, Begley AE, Dew MA, Mulsant BH, Zmuda MD, Bhalla R, Meltzer CC, Pollock BG, Reynolds CF III, Becker JT. The nature and determinants of neuropsychological functioning in late-life depression. Arch Gen Psychiatry. 2004;61(6):587-595.
30. Rogers JC, Holm MB, Raina KD, Dew MA, Shih MM, Begley A, Houck PR, Mazumdar S, Reynolds CF III. Disability in late-life major depression: patterns of self-reported task abilities, task habits, and observed task performance. Psychiatry Res. 2010;178(3):475-479.
31. Reynolds CF III, Frank E, Perel JM, Imber SD, Cornes C, Miller MD, Mazumdar S, Houck PR, Dew MA, Stack JA, Pollock BG, Kupfer DJ. Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression: a randomized controlled trial in patients older than 59 years. JAMA. 1999;281(1):39-45.
32. Reynolds CF III, Dew MA, Pollock BG, Mulsant BH, Frank E, Miller MD, Houck PR, Mazumdar S, Butters MA, Stack JA, Schlernitzauer MA, Whyte EM, Gildengers A, Karp J, Lenze E, Szanto K, Bensasi S, Kupfer DJ. Maintenance treatment of major depression in old age. N Engl J Med. 2006;354(11):1130-1138.
33. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457-481.
34. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81(3):515-526. doi:10.1093/biomet/81.3.515.
35. Gaynor JJ, Feuer EJ, Tan CC, Wu DH, Little CR, Straus DJ, Clarkson BD, Brennan MF. On the use of cause-specific failure and conditional failure probabilities: examples from clinical oncology data. J Am Stat Assoc. 1993;88(422):400-409.
36. Miller MD, Paradis CF, Houck PR, Mazumdar S, Stack JA, Rifai AH, Mulsant B, Reynolds CF III. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res. 1992;41(3):237-248.
37. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12(3):189-198.
38. Souery D, Oswald P, Massat I, Bailer U, Bollen J, Demyttenaere K, Kasper S, Lecrubier Y, Montgomery S, Serretti A, Zohar J, Mendlewicz J; Group for the Study of Resistant Depression. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry. 2007;68(7):1062-1070.
39. Pelton GH, Harper OL, Tabert MH, Sackeim HA, Scarmeas N, Roose SP, Devanand DP. Randomized double-blind placebo-controlled donepezil augmentation in antidepressant-treated elderly patients with depression and cognitive impairment: a pilot study. Int J Geriatr Psychiatry. 2008;23(7):670-676.
40. Holtzheimer PE III, Meeks TW, Kelley ME, Mufti M, Young R, McWhorter K, Vito N, Chismar R, Quinn S, Dey S, Byrd EH, McDonald WM. A double blind, placebocontrolled pilot study of galantamine augmentation of antidepressant treatment in older adults with major depression. Int J Geriatr Psychiatry. 2008;23(6): 625-631.
41. Doody RS, Ferris SH, Salloway S, Sun Y, Goldman R, Watkins WE, Xu Y, Murthy AK. Donepezil treatment of patients with MCI: a 48-week randomized, placebocontrolled trial. Neurology. 2009;72(18):1555-1561.
42. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ; Alzheimer's Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352(23):2379-2388.
43. Winblad B, Gauthier S, Scinto L, Feldman H, Wilcock GK, Truyen L, Mayorga AJ, Wang D, Brashear HR, Nye JS; GAL-INT-11/18 Study Group. Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology. 2008; 70(22):2024-2035.
44. Feldman HH, Ferris S, Winblad B, Sfikas N, Mancione L, He Y, Tekin S, Burns A, Cummings J, del Ser T, Inzitari D, Orgogozo JM, Sauer H, Scheltens P, Scarpini E, Herrmann N, Farlow M, Potkin S, Charles HC, Fox NC, Lane R. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol. 2007;6(6):501-512.